Q32 Bio Announces Merger Closing with Homology Medicines & Private Placement of $42 Million
Mar 25, 2024 CU Innovations University - News and events tagsQ32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced the completion of its merger with Homology Medicines, Inc. ("Homology").